{{Rsnum
|rsid=3780413
|Gene=SLC1A1
|Chromosome=9
|position=4567353
|Orientation=minus
|GMAF=0.3884
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=SLC1A1,SPATA6L
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 52.3 | 36.9 | 10.8
| HCB | 60.0 | 40.0 | 0.0
| JPT | 59.1 | 38.6 | 2.3
| YRI | 3.2 | 22.6 | 74.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 60.0 | 40.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19884611
|Title=Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms
}}

{{PharmGKB
|RSID=rs3780413
|Name_s=SLC1A1:rss3780413C>G, SNP3, Intron 5
|Gene_s=SLC1A1
|Feature=
|Evidence=PubMed ID:19884611
|Annotation=Risk or phenotype-associated variant: C. Phenotype: The A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with atypical antipsychotic-induced obsessive compulsive symptoms. Study size: 94. Study population/ethnicity: Patients with schizophrenia receiving atypical antipsychotics; Asian; Korea. Significance metric(s): p = 0.04. Type of association: CO.
|Drugs=clozapine; olanzapine; risperidone
|Drug Classes=
|Diseases=Obsessive-Compulsive Disorder; Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165110322
}}

{{PMID|22531293}} Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3780413
|overall_frequency_n=72
|overall_frequency_d=128
|overall_frequency=0.5625
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=59
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}